Trials / Completed
CompletedNCT05817240
A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
A Phase 1, Single-Center, Fixed Sequence, Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Endeavor Biomedicines, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib) on the pharmacokinetics of nintedanib (an approved treatment for idiopathic pulmonary fibrosis) when the two compounds are dosed together in healthy subjects. Participants in this study will receive ENV-101 and/or nintedanib on various days throughout a 10-day period during which they will reside at the clinical trial site.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | taladegib | 100 mg per tablet, dosed once daily |
| DRUG | nintedanib | 100 mg per capsule, dosed once daily |
Timeline
- Start date
- 2023-05-03
- Primary completion
- 2023-06-11
- Completion
- 2023-06-21
- First posted
- 2023-04-18
- Last updated
- 2023-12-15
Locations
1 site across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05817240. Inclusion in this directory is not an endorsement.